Seroatlas · Human Serome Atlas

ALYREF

THO complex subunit 4

Also known as: THOC4_HUMAN

Cross-references: UniProt · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q86V81
Gene: ALYREF
Canonical length: 257 aa
Protein class: Predicted intracellular proteins
Quaternary structure: Homomultimer

OverviewNCBI Gene

No narrative summary is available for ALYREF in this catalog release; identity and structured annotations are shown without generated factual claims.

Canonical amino-acid sequenceUniProt

257 residues, UniProt reviewed canonical sequence.

>Q86V81|ALYREF
     1  MADKMDMSLD DIIKLNRSQR GGRGGGRGRG RAGSQGGRGG GAQAAARVNR GGGPIRNRPA
    61  IARGAAGGGG RNRPAPYSRP KQLPDKWQHD LFDSGFGGGA GVETGGKLLV SNLDFGVSDA
   121  DIQELFAEFG TLKKAAVHYD RSGRSLGTAD VHFERKADAL KAMKQYNGVP LDGRPMNIQL
   181  VTSQIDAQRR PAQSVNRGGM TRNRGAGGFG GGGGTRRGTR GGARGRGRGA GRNSKQQLSA
   241  EELDAQLDAY NARMDTS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against ALYREF can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.58
Highest tissue expression: 141 nTPM

Expression across tissuesHPA

Tissue

bone marrow: 141 nTPM
testis: 68 nTPM
thymus: 61 nTPM
lymph node: 58 nTPM
skeletal muscle: 58 nTPM
esophagus: 55 nTPM

Single-cell type

erythrocyte progenitors: 160 nCPM
megakaryocytes: 99 nCPM
monocyte progenitors: 94 nCPM
megakaryocyte progenitors: 90 nCPM
gastric progenitor cells: 72 nCPM
pdcs: 59 nCPM

Immune cell

plasmacytoid DC: 2.2 nTPM
gdT-cell: 1.5 nTPM
intermediate monocyte: 1.2 nTPM
myeloid DC: 1.2 nTPM
naive B-cell: 1.2 nTPM
classical monocyte: 1.1 nTPM

Brain region

white matter: 33 nTPM
spinal cord: 31 nTPM
pons: 31 nTPM
cerebral cortex: 31 nTPM
midbrain: 30 nTPM
thalamus: 29 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about ALYREF.

Disease | ImmuneIEDB

Conditions an epitope on ALYREF was assayed in.

skin melanoma T cell

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.36
gnomAD pLI: 0.93
gnomAD missense Z: 2.31
DepMap mean gene effect: -1.34
DepMap dependency class: pan

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 8% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of ALYREF in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads ALYREF as an antibody target. Whether an autoantibody or antibody against ALYREF could matter depends on whether native ALYREF is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

ALYREF is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label ALYREF as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...